Clinical trial
Randomized, Two-Way Crossover, Single-Dose, Fasting Bioequivalence Study of Lamotrigine 1 x 200 mg Tablet
NCT00834561 is registered in ClinicalTrials.gov with Teva Pharmaceuticals USA as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Randomized, Two-Way Crossover, Single-Dose, Fasting Bioequivalence Study of Lamotrigine 1 x 200 mg Tablet
- Lead sponsor
- Teva Pharmaceuticals USA
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- January 31, 2002
- Completion date
- February 28, 2002
- Enrollment
- 32 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
healthy